Can low free T3 raise blood glucose by reducing peripheral insulin sensitivity even when TSH and free T4 are normal?

The relationship between thyroid signaling and glucose metabolism is complex, as thyroid hormones exert different effects on the liver compared to peripheral tissues like muscle and fat. While low free T3 (fT3) can indeed impair peripheral insulin sensitivity, it does not typically increase hepatic glucose output; rather, T3 itself is a primary driver of glucose production in the liver.

Effects on insulin sensitivity

Low levels of fT3 are associated with reduced insulin sensitivity in peripheral tissues, which can contribute to higher blood glucose levels.

• Mechanistic findings: T3 is essential for the upregulation of GLUT4, the primary glucose transporter in skeletal muscle and adipocytes. When fT3 levels are low, there is a reduction in insulin-stimulated glucose uptake. Research indicates that T3 also acutely stimulates glucose transport independently of the standard insulin-signaling pathways (PI3K-Akt).
• Clinical evidence: In euthyroid and non-diabetic populations, lower fT3 levels have been shown to independently predict higher HOMA-IR values (a marker of insulin resistance), even after adjusting for age and BMI. However, some studies in obese populations show a paradoxical positive correlation between fT3 and insulin resistance, which may represent a compensatory response to metabolic stress.

Effects on hepatic glucose output

The claim that low fT3 increases hepatic glucose output is not supported by current evidence; T3 signaling actually stimulates the production of glucose in the liver.

• Molecular pathways: T3 increases hepatic glucose output by inducing the transcription of key gluconeogenic enzymes, including phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase). This occurs through the activation of thyroid hormone receptor beta (THRB) and the deacetylation of the transcription factor FoxO1.
• Systemic regulation: In addition to direct hepatic effects, T3 acts on the central nervous system (specifically the hypothalamic paraventricular nucleus) to increase endogenous glucose production via sympathetic neural projections. Consequently, states of low fT3 (hypothyroidism) are characterized by decreased rather than increased hepatic glucose production.

Clinical implications for "normal" thyroid panels

Metabolic dysfunction can persist even when TSH and free T4 (fT4) are within the standard reference range, particularly if peripheral conversion of T4 to T3 is suboptimal.

• Deiodinase activity: The conversion of T4 to the active T3 is mediated by the DIO2 enzyme. Genetic polymorphisms, such as the Thr92Ala variant, are associated with higher fasting glucose and HbA1c in euthyroid individuals, suggesting that localized "tissue hypothyroidism" can drive hyperglycemia despite normal serum TSH.
• Levothyroxine monotherapy: Patients on T4-only replacement therapy often exhibit lower fT3/fT4 ratios. In these individuals, a lower fT3 level may signify a failure to achieve physiological T3 levels in peripheral tissues, potentially contributing to persistent metabolic issues even when TSH is normalized.

Bottom line

Low free T3 is a plausible contributor to higher glucose levels primarily through reduced peripheral insulin sensitivity and impaired GLUT4 expression. However, it does not increase hepatic glucose output; instead, T3 signaling is a known activator of liver glucose production. In patients with "normal" TSH and fT4, a low fT3 may indicate suboptimal peripheral conversion that negatively impacts glycemic control.